Synapse - Find an Expert

115372 Results

PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer

Meeting Abstract

Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Meeting Abstract

Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaïve, RET-mutant medullary thyroid cancer

Meeting Abstract

Hadoux, J.; Elisei, R.; Brose, M. S.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas

Meeting Abstract

Jones, R. L.; Sanfilippo, R.; Schuetze, S. M.; Sebio, A.; Alvarez, R. M.; Bui, N.; Wagner, A. J.; Chawla, S. P.; Chen, T. W. W.; Pink, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Meeting Abstract

Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S; Rathkopf, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Meeting Abstract

Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Meeting Abstract

Ajani, J. A.; Lordick, F.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study